Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06666660

Daily Intake of Multivitamin & Mineral Supplementation Effects on Biological Age of Relatively Healthy Middle-aged Individuals

Sponsor: National University of Singapore

View on ClinicalTrials.gov

Summary

Micronutrients, such as vitamins and minerals, are required to sustain fundamental physiological processes in individuals. As individuals age, the risk of having suboptimal levels of micronutrients increases due to several age-related changes affecting their digestion and assimilation processes. Suboptimal levels of micronutrients have been associated with increased risk of chronic diseases and accelerated ageing. Three years intake of a multivitamin and mineral supplement (MVM) improved global cognition, episodic memory and executive function in older adults. Furthermore, suboptimal micronutrient levels have been associated with a higher biological age, and diet and lifestyle interventions might lower the biological age measured by methylation clocks. Therefore, further evaluation is warranted to determine if MVM supplementation could improve the biological age and clinical outcomes in individuals with a higher biological age.

Official title: Centrum; the Effect of Daily Intake of Multivitamin & Mineral Supplementation, on Biological Age in Relatively Healthy Middle-aged Individuals (CEDIRA)

Key Details

Gender

All

Age Range

40 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2024-09-23

Completion Date

2025-06-30

Last Updated

2024-10-30

Healthy Volunteers

Yes

Conditions

Relatively Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Multivitamin/Mineral supplements

Each participant will be given 180 MVM tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally daily, in the morning before food. Participants will be asked to return the remainder of dispensed MVM tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm.

OTHER

Placebo

Each participant will be given 180 placebo tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally, daily, in the morning before food. Participants will be asked to return the remainder of dispensed placebo tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm. The placebo pills and bottles will be identical in appearance as MVM to ensure effective blinding.

Inclusion Criteria Participants will be recruited if they fall in the following categories: 1. Relatively healthy middle aged (40-60 years) man or woman; 2. Completed the pre-screening requirements and has managed to schedule the screening visit; 3. Met the randomization criteria after the screening visit i.e., your biological age (as measured by blood DNA methylation) is greater than the chronological age; 4. Able to attend all 4 research visits for screening and research data collection at the NUHS Centre for Healthy Longevity (CHL) at Alexandra Hospital or MD11, National University of Singapore. 5. Willing to wear an OURA ring for 14 consecutive days after each study visits. 6. Willing to download study platform application into their mobile phone throughout the study period. Exclusion Criteria Participants will NOT be recruited if they fall in any one or more of the following categories: 1. BMI lower than 18 kg/m2 or higher than or equal to 30 kg/m2 \[25\]; 2. Pre-existing, or history of major cardiovascular diseases (coronary artery disease, heart failure, stroke, peripheral vascular disease, pulmonary hypertension), severe/uncontrolled hypertension (more than 1 prescribed medication), rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism; 3. Type 1 diabetes and Type 2 diabetes; 4. Active cancer or treatment of cancer in the last 3 years; 5. Chronic obstructive pulmonary disease (COPD), severe asthma (taking daily medications); 6. Pregnant women or women planning pregnancy in the next 12 months; 7. Multiple sclerosis or autoimmune/immune deficiency diseases such as Rheumatic arthritis, HIV, Crohn's disease; 8. Recent history of sepsis or infection (within 3 months of in-patient hospitalisation); 9. Any psychiatric disease or neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Lewy body dementia, and any eating disorders; 10. Hepatitis and liver cirrhosis (independent of severity); 11. Severe kidney disease (GFR less than 30 ml/min/1.73 m2); 12. Skin disease (on systemic medication); 13. Individuals who are on another trial that requires them taking similar or partially similar investigational product (Appendix 1); 14. Individuals who are advised by their medical practitioner to take a MVM supplement; 15. Refuse to stop taking any non-prescribed supplements that contain the investigational product (Appendix 1) within one month before the screening visit and during the study period; 16. Taking a medically prescribed supplements that contains 2 or more of the ingredients of the investigational product (Appendix 1); 17. Individuals with planned hospitalization in the next 12 months; 18. Any serious medical illness which in the PI's judgment may jeopardise the participant by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study.

Locations (2)

Healthy Longevity Translational Research Programme, Level 3, MD 11, 10 Medical Dr, Yong Loo Lin School of Medicine, National University of Singapore

Singapore, Singapore, Singapore

Center for Healthy Longevity, Clinic L, Alexandra Hospital, 378 Alexandra Road